Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 14 Other hematologic neoplasm 12 Plasma cell 8 Thoracic 6 Gastrointestinal 3 Gynecologic 2 Tumor-Agnostic 1 Myeloid 1 Head & Neck 1 Genitourinary 1 Dermatologic 1 CNS 1 Breast 1

Conditions

Neoplasm, Residual 1 Neoplasm Metastasis 1

Interventions

pembrolizumab 94 Paclitaxel 85 Gemcitabine 83 Carboplatin 79 Docetaxel 60 Cisplatin 58 Bevacizumab 58 Nivolumab 56 Fluorouracil 47 Capecitabine 46 Magnetic Resonance Spectroscopy 44 Radiotherapy 41 Irinotecan 40 Oxaliplatin 38 Erlotinib Hydrochloride 37 Pemetrexed 34 Leucovorin 34 Biopsy 34 atezolizumab 33 Cetuximab 32 Standard of Care 31 Trastuzumab 28 Cyclophosphamide 28 Blood Specimen Collection 28 Radiosurgery 27 Specimen Handling 26 Sorafenib 26 Ipilimumab 26 Everolimus 26 olaparib 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Maintenance × Tumor-Agnostic × Clear all

NCT02067143 2021-09-08

LAL1913

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2 Completed

Neoplasm Metastasis, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡